Profile of elotuzumab and its potential in the treatment of multiple myeloma

References

• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;17; 364(11):1046–1060.
   PubMed Web of Science ®Google Scholar
• Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012;9(3):135–143.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Ocio EM, San Miguel JF. Novel generation of agents with proven clinical activity in multiple myeloma. Semin Oncol. 2013;40(5):618–633.
   Web of Science ®Google Scholar
• Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120(5):947–959.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149–157.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276–2284.
   PubMed Web of Science ®Google Scholar
• Ocio EM, Richardson PG, Rajkumar SV, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 201428(3):525–542.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson KC. New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013;19(13):3337–3344.
   PubMed Web of Science ®Google Scholar
• Anderson KC. The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 2012;30(4):445–452.
   Web of Science ®Google Scholar
• Allegra A, Penna G, Alonci A, et al. Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol. 2013;90(6):441–468.
   PubMed Web of Science ®Google Scholar
• van de Donk NW, Kamps S, Mutis T, Lokhorst HM. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia. 2012;26(2):199–213.
   PubMed Web of Science ®Google Scholar
• Tai YT, Anderson KC. Antibody-based therapies in multiple myeloma. Bone Marrow Res. 2011;2011:924058.
   PubMedGoogle Scholar
• Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC. Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 2011;21. doi: 10.1111/j.1365-2141.2011.08790.x
   Web of Science ®Google Scholar
• Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020–2028.
   PubMed Web of Science ®Google Scholar
• Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol. 2008;141(2):135–148.
   PubMed Web of Science ®Google Scholar
• Moreau P, Voillat L, Benboukher L, et al; IFM group. Rituximab in CD20 positive multiple myeloma. Leukemia. 2007;21(4):835–836.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775–2784.
   PubMed Web of Science ®Google Scholar
• Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4):1329–1337.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009;8(9):2616–2624.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Mohrbacher AF, Singhal S, et al. A Phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood. 2012;120(3):552–559.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Bensinger W, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012;30(16):1960–1965.
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30(16):1953–1959.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Jagannath S, Moreau P, et al. A Phase 2 study of elotuzumab (elo) in combination with lenalidomide and low-dose dexamethasone (ld) in patients (pts) with relapsed/refractory multiple myeloma (r/r mm): updated results. Blood (ASH Annual Meeting Abstracts). 2012;120: Abstract 202.
   Google Scholar
• Lonial S, Jagannath S, Moreau P, et al. Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety. J Clin Oncol. 2013;31:15(Suppl): Abstract 8542.
   Web of Science ®Google Scholar
• Lonial S, Kaufman J, Laubach J, Richardson P. Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. Expert Opin Biol Ther. 2013;13(12):1731–1740.
   PubMed Web of Science ®Google Scholar
• Bouchon A, Cella M, Grierson HL, Cohen JI, Colonna M. Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol. 2001;167(10):5517–5521.
   PubMed Web of Science ®Google Scholar
• Kumaresan PR, Lai WC, Chuang SS, Bennett M, Mathew PA. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol. 2002;39(1–2):1–8.
   PubMed Web of Science ®Google Scholar
• Cannons JL, Tangye SG, Schwartzberg PL. SLAM family receptors and SAP adaptors in immunity. Annu Rev Immunol. 2011;29:665–705.
   PubMed Web of Science ®Google Scholar
• Schwartzberg PL, Mueller KL, Qi H, Cannons JL. SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat Rev Immunol. 2009;9(1):39–46.
   Web of Science ®Google Scholar
• Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol. 2013;88(1):168–177.
   PubMed Web of Science ®Google Scholar
• Cruz-Munoz ME, Dong Z, Shi X, Zhang S, Veillette A. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. Nat Immunol. 2009;10(3):297–305.
   PubMed Web of Science ®Google Scholar
• Tassi I, Colonna M. The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cgamma signaling pathways in human NK cells. J Immunol. 2005;175(12):7996–8002.
   PubMed Web of Science ®Google Scholar
• Lee JK, Mathew SO, Vaidya SV, Kumaresan PR, Mathew PA. CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes. J Immunol. 2007;179(7):4672–4678.
   PubMed Web of Science ®Google Scholar
• Stark S, Watzl C. 2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells. Int Immunol. 2006;18(2):241–247.
   Web of Science ®Google Scholar
• De Salort J, Sintes J, Llinàs L, Matesanz-Isabel J, Engel P. Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: from pro-B to plasma cells. Immunol Lett. 2011;134(2):129–136.
   PubMed Web of Science ®Google Scholar
• Bae J, Song W, Smith R, et al. A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Br J Haematol. 2012;157(6):687–701.
   PubMed Web of Science ®Google Scholar
• Tai YT, Soydan E, Song W, et al. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood. 2009;113(18):4309–4318.
   PubMed Web of Science ®Google Scholar
• Rice A, Dillon M, van Abbema A, et al. Eradication of tumors in pre-clinical models of multiple myeloma by anti-cs1 monoclonal antibody HuLuc63: mechanism of action studies. Blood (ASH Annual Meeting Abstracts). 2006;108: Abstract 3503.
   Web of Science ®Google Scholar
• Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62(12):1841–1849.
   PubMed Web of Science ®Google Scholar
• Godfrey J, Benson DM. The role of natural killer cells in immunity against multiple myeloma. Leuk Lymphoma. 2012;53(9):1666–1676.
   PubMed Web of Science ®Google Scholar
• Garg TK, Szmania SM, Khan JA, et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012;97(9):1348–1356.
   PubMed Web of Science ®Google Scholar
• Szmania S, Garg TK, Lapteva N, et al. Fresh ex vivo expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma (mm) patients. Blood (ASH Annual Meeting Abstracts). 2012;120: Abstract 579.
   Google Scholar
• Garg TK, Szmania S, Shi J, et al. Ex vivo activated natural killer (NK) cells from myeloma patients kill autologous myeloma and killing is enhanced by elotuzumab. Blood (ASH Annual Meeting Abstracts). 2008;112: Abstract 3666.
   Google Scholar
• Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–2498.
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133–2142.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;22;357(21):2123–2132.
   PubMed Web of Science ®Google Scholar
• Neyer L, Ding H, Chen D, et al. Effect of elotuzumab on circulating lymphocytes, chemokines, and cytokines in multiple myeloma patients. Blood (ASH Annual Meeting Abstracts). 2010;116: Abstract 4070.
   Google Scholar
• Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–733.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518.
   PubMed Web of Science ®Google Scholar
• Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28(4):917–927.
   PubMed Web of Science ®Google Scholar
• Bae J, Smith R, Daley J, et al. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res. 2012;18(17):4850–4860.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Hernández MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013;369(5):438–447.
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–1848.
   PubMed Web of Science ®Google Scholar
• Plesner T, Lokhorst H, Gimsing P, Nahi H, Lisby S, Richardson PG. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma – data from a dose-escalation Phase I/II study. Blood (ASH Annual Meeting Abstracts). 2012;120: Abstract 73.
   Google Scholar